As on Wednesday, Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) started slowly as it slid -8.15% to $13.41, before settling in for the price of $14.6 at the close. Taking a more long-term approach, RDY posted a 52-week range of $12.26-$16.17.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 19.33%. Meanwhile, its Annual Earning per share during the time was 19.33%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -10.86%. This publicly-traded company’s shares outstanding now amounts to $834.61 million, simultaneously with a float of $832.34 million. The organization now has a market capitalization sitting at $11.16 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.36, while the 200-day Moving Average is $14.13.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Drug Manufacturers – Specialty & Generic industry. Dr. Reddy’s Laboratories Ltd. ADR’s current insider ownership accounts for 0.00%, in contrast to 13.32% institutional ownership.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Earnings and Revenue Records
Dr. Reddy’s Laboratories Ltd. ADR’s EPS decrease for this current 12-month fiscal period is -10.86% and is forecasted to reach 0.64 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -1.49% through the next 5 years, which can be compared against the 19.33% growth it accomplished over the previous five years trading on the market.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Trading Performance Indicators
Let’s observe the current performance indicators for Dr. Reddy’s Laboratories Ltd. ADR (RDY). It’s Quick Ratio in the last reported quarter now stands at 1.35. Alongside those numbers, its PE Ratio stands at $16.42, and its Beta score is 0.38. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.81. Similarly, its price to free cash flow for trailing twelve months is now 81.46.
In the same vein, RDY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.82, a figure that is expected to reach 0.16 in the next quarter, and analysts are predicting that it will be 0.64 at the market close of one year from today.
Technical Analysis of Dr. Reddy’s Laboratories Ltd. ADR (RDY)
Through scrutinizing the latest numbers posted by the [Dr. Reddy’s Laboratories Ltd. ADR, RDY], it can be observed that its last 5-days Average volume of 1.68 million was better the volume of 1.65 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 43.46% While, its Average True Range was 27.31.
Raw Stochastic average of Dr. Reddy’s Laboratories Ltd. ADR (RDY) in the period of the previous 100 days is set at 8.91%, which indicates a major fall in contrast to 14.94% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.29 that was higher than 0.20 volatility it exhibited in the past 100-days period.
